Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

ClinicalTrials.gov ID: NCT07287189

Public ClinicalTrials.gov record NCT07287189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.

Study identification

NCT ID: NCT07287189
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Satellos Bioscience, Inc.; Industry
Enrollment: 51 participants

Conditions and interventions

Conditions

Interventions

SAT-3247 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 7 Years to 9 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 7, 2025
Primary completion: Mar 30, 2027
Completion: Feb 27, 2028
Last update posted: Aug 13, 2026

2025 – 2028

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
University of California Los Angeles	Los Angeles	California	90095	Recruiting
Colorado Children's	Aurora	Colorado	80045	Recruiting
Lurie Children's	Chicago	Illinois	60611	Recruiting
UMass Memorial Medical Center	Worcester	Massachusetts	01655	Recruiting
Washington University	St Louis	Missouri	63110	Recruiting
Nationwide Children's Hospital	Columbus	Ohio	43205	Recruiting
Seattle Children's	Seattle	Washington	98105	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07287189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 13, 2026 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07287189 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →